Conduit Pharmaceuticals Stock Market Value
| CDT Stock | 1.10 0.02 1.79% |
| Symbol | Conduit |
Is there potential for Life Sciences Tools & Services market expansion? Will Conduit introduce new products? Factors like these will boost the valuation of Conduit Pharmaceuticals. Projected growth potential of Conduit fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Conduit Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Conduit Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Conduit's accounting equity. The concept of intrinsic value - what Conduit Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Conduit Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Conduit Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Conduit Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Conduit Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Conduit Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Conduit Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Conduit Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Conduit Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Conduit Pharmaceuticals or generate 0.0% return on investment in Conduit Pharmaceuticals over 90 days. Conduit Pharmaceuticals is related to or competes with Longevity Health, ZyVersa Therapeutics, Envoy Medical, Scworx Corp, Lixte Biotechnology, NewGenIvf Group, and Concord Medical. Conduit Pharmaceuticals is entity of United States More
Conduit Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Conduit Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Conduit Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 40.12 | |||
| Value At Risk | (13.57) | |||
| Potential Upside | 12.43 |
Conduit Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Conduit Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Conduit Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Conduit Pharmaceuticals historical prices to predict the future Conduit Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.22) | |||
| Total Risk Alpha | (1.81) | |||
| Treynor Ratio | (0.33) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Conduit Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Conduit Pharmaceuticals February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 5.25 | |||
| Coefficient Of Variation | (769.18) | |||
| Standard Deviation | 7.27 | |||
| Variance | 52.92 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (1.22) | |||
| Total Risk Alpha | (1.81) | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 40.12 | |||
| Value At Risk | (13.57) | |||
| Potential Upside | 12.43 | |||
| Skewness | (0.06) | |||
| Kurtosis | 1.21 |
Conduit Pharmaceuticals Backtested Returns
Conduit Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. Conduit Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Conduit Pharmaceuticals' Risk Adjusted Performance of (0.09), standard deviation of 7.27, and Mean Deviation of 5.25 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.86, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. At this point, Conduit Pharmaceuticals has a negative expected return of -0.89%. Please make sure to confirm Conduit Pharmaceuticals' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Conduit Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.41 |
Average predictability
Conduit Pharmaceuticals has average predictability. Overlapping area represents the amount of predictability between Conduit Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Conduit Pharmaceuticals price movement. The serial correlation of 0.41 indicates that just about 41.0% of current Conduit Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.41 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.